Detalhe da pesquisa
1.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(5): 1008-1011, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38425185
2.
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.
Am J Hematol
; 98(11): 1685-1698, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37548390
3.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
Inglês
| MEDLINE | ID: mdl-31433920
4.
Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation.
Haematologica
; 106(2): 363-374, 2021 02 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31879324
5.
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
BMC Cancer
; 21(1): 993, 2021 Sep 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34488662
6.
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
Ann Hematol
; 100(6): 1537-1546, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-33575947
7.
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
Br J Cancer
; 121(9): 751-757, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31558804
8.
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes.
Blood
; 130(26): 2838-2847, 2017 12 28.
Artigo
Inglês
| MEDLINE | ID: mdl-29089311
9.
Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
Biol Blood Marrow Transplant
; 22(11): 1988-1996, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27590108
10.
'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Eur J Haematol
; 97(1): 25-32, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26331915
11.
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.
Blood
; 129(25): 3386-3388, 2017 06 22.
Artigo
Inglês
| MEDLINE | ID: mdl-28476749
12.
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Ann Hematol
; 93(11): 1825-38, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24951123
13.
CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1.
Leukemia
; 38(1): 181-192, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37898670
14.
[11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions.
Br J Haematol
; 181(5): 701-703, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28466502
15.
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Br J Haematol
; 161(5): 695-700, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23565715
16.
Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance.
Haematologica
; 103(3): e126-e129, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29191843
17.
SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.
EClinicalMedicine
; 58: 101910, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-36969337
18.
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT.
Cancers (Basel)
; 15(5)2023 Feb 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36900181
19.
The gross picture: intraindividual tumour heterogeneity in a patient with nonsecretory multiple myeloma.
Eur J Nucl Med Mol Imaging
; 44(6): 1097-1098, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28238021
20.
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.
Cancers (Basel)
; 14(10)2022 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35626063